Your email has been successfully added to our mailing list.

×
-0.00594059405940581 -0.00594059405940581 -0.00594059405940581 -0.00594059405940581 0.0297029702970298 0.0336633663366338 0.223762376237624 0.108910891089109
Stock impact report

Oncternal Therapeutics Announces Presentation of Update on Phase 1/2 Clinical Trial of Cirmtuzumab in Combination with Ibrutinib at 2020 ASCO Annual Meeting

Oncternal Therapeutics, Inc. (ONCT) 
Last oncternal therapeutics, inc. earnings: 8/8 04:01 pm Check Earnings Report
Company Research Source: Business Wire
58% complete response rate reported for patients with relapsed/refractory MCL, with a median follow-up of 8.3 months 100% progression-free survival reported for patients with CLL, with a median follow-up of 12.8 monthsCirmtuzumab continued to be well tolerated in this trial SAN DIEGO--(BUSINESS WIRE)--Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced updated interim clinical data from the ongoing Phase 1/2 CIRLL (Cirmtuzumab and Ibrutinib targeting ROR1 for Leukemia and Lymphoma) clinical trial, in which cirmtuzumab, an investigational anti-ROR1 monoclonal antibody, is being evaluated in combination with ibrutinib in patients with mantle cell lymphoma (MCL) or chronic lymphocytic leukemia (CLL). The data will be presented as part of the American Society of Clinical Oncology (ASCO) 2020 Virtual Annual Meeting, and a copy of the poster presentation will be available online at Show less Read more
Impact Snapshot
Event Time:
ONCT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
Last price at news event
Since Event
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
Last Price
VWAP
High:
Max Up
High:
Low:
Max Down
Low:
%
Post news range
%
Price change

Price Change Percentage


S&P 500
(SPX)

%

Volume ratio
%

Volume
Ticks

Avg transaction size

Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Opt-in for
ONCT alerts

from News Quantified
Opt-in for
ONCT alerts

from News Quantified